In the remaining patients, poor response to IFNβ might relate to the nature of the IFNβ response, a relationship that could yield insight to the pathogenesis of MS, as well as strategies to personalize the use of IFNβ. The gene discussed is IFNB1; the disease is myeloid sarcoma.